| Literature DB >> 28204978 |
Aleksandra Tesmar1, Dariusz Wyrzykowski2, Rafał Kruszyński3, Karolina Niska4, Iwona Inkielewicz-Stępniak4, Joanna Drzeżdżon1, Dagmara Jacewicz1, Lech Chmurzyński1.
Abstract
The use of protonated N-heterocyclic compound, i.e. 2,2'-bipyridinium cation, [bpyH+], enabled to obtain the new nitrilotriacetate oxidovanadium(IV) salt of the stoichiometry [bpyH][VO(nta)(H2O)]H2O. The X-ray measurements have revealed that the compound comprises the discrete mononuclear [VO(nta)(H2O)]- coordination ion that can be rarely found among other known compounds containing nitrilotriacetate oxidovanadium(IV) moieties. The antitumor activity of [bpyH][VO(nta)(H2O)]H2O and its phenanthroline analogue, [phenH][VO(nta)(H2O)](H2O)0.5, towards human osteosarcoma cell lines (MG-63 and HOS) has been assessed (the LDH and BrdU tests) and referred to cis-Pt(NH3)2Cl2 (used as a positive control). The compounds exert a stronger cytotoxic effect on MG-63 and HOS cells than in untransformed human osteoblast cell line. Thus, the [VO(nta)(H2O)]- containing coordination compounds can be considered as possible antitumor agents in the osteosarcoma model of bone-related cells in culture.Entities:
Keywords: Antitumor activity; Crystal structure; Osteosarcoma cells; Potentiometric titration; Vanadium
Mesh:
Substances:
Year: 2017 PMID: 28204978 PMCID: PMC5352783 DOI: 10.1007/s10534-017-0001-6
Source DB: PubMed Journal: Biometals ISSN: 0966-0844 Impact factor: 2.949
Fig. 1Schematic molecular structures of VO(maltolato)2 (BMOV) and VO(Etmaltolato)2 (BEOV)
Fig. 2Anti-tumor vanadium coordination compounds
Fig. 3Structural formulae of VO-oda coordination compounds
Crystal and structure refinement data of [bpyH][VO(nta)(H2O)]H2O
| Compound | [bpyH][VO(nta)(H2O)]H2O |
|---|---|
| Empirical formula | C16H19N3O9V |
| Formula weight | 448.28 |
| Crystal system, space group | Monoclinic, |
| Unit cell dimensions (Å, °) |
|
|
| |
|
| |
|
| |
| Volume (Å3) | 1803.8(4) |
| Z, Calculated density (Mg/m3) | 4, 1.651 |
|
| 924 |
| Crystal size (mm) | 0.120, 0.116, 0.109 |
|
| 3.480 to 72.401 |
| Index ranges | −7 ≤ |
| Reflections collected/unique | 19203/3547 (R |
| Completeness (%) | 99.9 (to |
| Data/restraints/parameters | 3547/0/263 |
| Goodness-of-fit on | 1.064 |
| Final |
|
| R indices (all data) |
|
| Largest diff. peak and hole (e·Å−3) | 0.394, −0.419 |
Fig. 4The molecular structure of [bpyH][VO(nta)(H2O)]H2O. Displacement ellipsoids are drawn at the 50% probability level, hydrogen atoms are drawn as spheres of arbitrary radii
Selected structural data of [bpyH][VO(nta)(H2O)]H2O
| Distance/angle | Å, ° |
|---|---|
| V1—O8 | 1.5991 (10) |
| V1—O5 | 1.9927 (10) |
| V1—O1 | 1.9930 (10) |
| V1—O7 | 2.0181(10) |
| V1—O3 | 2.0250 (10) |
| V1—N1 | 2.3416 (11) |
| N11—C11 | 1.3415 (19) |
| N11—C15 | 1.3477 (18) |
| N12—C16 | 1.3463 (18) |
| N12—C20 | 1.3363 (19) |
| O1—C1 | 1.2876 (16) |
| O2—C1 | 1.2355 (17) |
| O3—C3 | 1.2804 (16) |
| O4—C3 | 1.2386 (17) |
| O5—C5 | 1.2792 (16) |
| O6—C5 | 1.2408 (17) |
| O8—V1—O5 | 104.02 (5) |
| O8—V1—O1 | 104.02 (5) |
| O5—V1—O1 | 150.45 (4) |
| O8—V1—O7 | 100.92 (5) |
| O5—V1—O7 | 85.47 (4) |
| O1—V1—O7 | 87.40 (4) |
| O8—V1—O3 | 94.47 (5) |
| O5—V1—O3 | 89.31 (4) |
| O1—V1—O3 | 90.03 (4) |
| O7—V1—O3 | 164.54 (4) |
| O8—V1—N1 | 171.60 (5) |
| O5—V1—N1 | 75.02 (4) |
| O1—V1—N1 | 76.04 (4) |
| O7—V1—N1 | 87.37 (4) |
| O3—V1—N1 | 77.22 (4) |
| C11—N11—C15 | 123.65 (12) |
| C20—N12—C16 | 117.27 (12) |
The hydrogen bonds geometry of [bpyH][VO(nta)(H2O)]H2O [Å, °]
| D—H···A | d(D-H) | d(H···A) | d(D···A) | <(DHA) |
|---|---|---|---|---|
| O7—H7O···O2i | 0.87 | 1.78 | 2.6492 (14) | 172.2 |
| O7—H7P···O6vi | 0.84 | 1.75 | 2.5855 (14) | 170.0 |
| N11—H11 N···O4 | 0.92 | 2.00 | 2.7980 (15) | 144.1 |
| N11—H11 N···N12 | 0.92 | 2.23 | 2.6349 (17) | 105.8 |
| O99—H99O···O3v | 0.91 | 2.02 | 2.9257 (14) | 176.0 |
| O99—H99P···O4 | 0.92 | 1.92 | 2.8253 (14) | 167.9 |
| C4—H4A···N12 | 0.99 | 2.67 | 3.5466 (18) | 148.4 |
| C6—H6A···O1i | 0.99 | 2.66 | 3.3954 (16) | 131.6 |
| C6—H6B···O2i | 0.99 | 2.61 | 3.3442 (16) | 131.3 |
| C14—H14···O99iii | 0.95 | 2.60 | 3.5308 (19) | 166.8 |
| C17—H17···O99iii | 0.95 | 2.57 | 3.4289 (18) | 150.9 |
| C18—H18···O8vii | 0.95 | 2.33 | 3.1162 (18) | 139.5 |
| C19—H19···O1iv | 0.95 | 2.57 | 3.4800 (17) | 161.3 |
| C20—H20···O6 | 0.95 | 2.41 | 3.2251 (17) | 144.1 |
Symmetry transformations used to generate equivalent atoms: (i) −x + 1/2, y − 1/2, −z + 3/2; (ii) −x + 3/2, y − 1/2, −z + 3/2; (iii) −x + 2, −y + 1, −z + 1; (iv) x, y − 1, z; (v) − x + 1, − y + 2, −z + 1; (vi) −x + 1/2, y + 1/2, − z + 3/2; (vii) x + 1, y − 1, z
Stacking interactions [Å, °]
| R (I)···R (J) | Cg···Cg | α | β | dp |
|---|---|---|---|---|
| Cg (1)···Cg (1)iii | 4.7663 (10) | 0 | 45.05 | −3.3672 (5) |
| Cg (1)···Cg (2)iii | 3.7910 (9) | 9.46 (7) | 29.70 | −3.5246 (5) |
| Cg (2)···Cg (1)iii | 3.7909 (9) | 9.46 (7) | 21.61 | −3.2928 (6) |
Cg(1), Cg(2) indicates the centroids of six-membered aromatic rings (R) containing N11, N22 atoms respectively, α is a dihedral angle between planes I and J, β is an angle between Cg(I) and Cg(J) vector and normal to plane I and dp is a perpendicular distance of Cg(I) on ring J plane
Symmetry transformations as in Table 3
Logarithms of equilibrium constants of complex species at 298.15 K (standard deviation values in parentheses)
| No. | Reaction | (bpyH) | (phenH) |
|---|---|---|---|
| 1 | A + H3O+
| 4.47 (0.03)a | 5.00 (0.04)a |
| 2 |
| 7.80 (0.06) | 7.93 (0.07) |
| 3 |
| −19.94 (0.06) | −19.91 (0.08) |
aLiterature data: the values of pK a of bpyH+ and phenH+ are 4.52 (Jakusch et al. 2002) and 4.93 (Duma and Hancock 1994), respectively
Fig. 5Species distribution curves of the VO(IV) species as a function of pH calculated based on the equilibrium constants for [bpyH][VO(nta)(H2O)] listed in Table 5
Fig. 6The viability of the human osteoblast cell line (hFOB 1.10) detected by the LDH test after 48 h of an exposure to investigated compounds and cisplatin (as a positive control). Data are expressed as mean values ± SD from three experiments. ***p < 0.001 versus control
Fig. 7The viability of the human osteosarcoma cell line (MG-63) assessed by the LDH test after 48 h of an exposure to investigated compounds and cisplatin (as a positive control). Data are expressed as mean values ± SD from three experiments. **p < 0.01; ***p < 0.001 versus control
Fig. 8The inhibition of the human osteosarcoma cell (MG-63) proliferation after an incubation with investigated compounds assessed with the BrdU-test. Cells were incubated with increasing concentrations of the tested compounds and cisplatin (as a positive control) for 48 h. Data are expressed as mean values ± SD from three experiments. ***p < 0.001 versus control
Fig. 9The inhibition of the human osteosarcoma cell (HOS) proliferation after an incubation with investigated compounds assessed with the BrdU-test. Cells were incubated with increasing concentrations of the tested compounds and cisplatin (as a positive control) for 48 h. Data are expressed as mean values ± SD from three experiments. ***p < 0.001 versus control